Expression of caveolin-1 is associated with poor prognosis of patients with squamous cell carcinoma of the lung

Lung Cancer

Volumn 42, Issue 2, 2003, Pages 195-202

  Yoo, Seong Ho ^a   Park, Young Sik ^a   Kim, Hyeong Ryul ^a   Sung, Sook Whan ^a   Kim, Joo Hyun ^a   Shim, Young Soo ^a   Lee, Soong Deok ^a   Choi, Yoon La ^a   Kim, Min Kyung ^b   Chung, Doo Hyun ^a  

^a Seoul National University   (South Korea)

^b Inje University College of Medicine   (South Korea)

Author keywords

Caveolin 1; Lung; Pathologic stage; Prognosis; Squamous cell carcinoma

Indexed keywords

CAVEOLIN 1;

ARTICLE; CANCER; CANCER STAGING; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE COURSE; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; IN VIVO STUDY; LUNG SQUAMOUS CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; STATISTICAL ANALYSIS; TREATMENT OUTCOME;

EID: 10744229744     PISSN: 01695002     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0169-5002(03)00287-3     Document Type: Article

References (40)

1. Mountain C.F. Prognostic implications of the international staging system for lung cancer. Semin. Oncol. 15:1988;236-245.
2. Li S., Couet J., Lisanti M.P. Src tyrosine kinases, Galpha subunits, and H-Ras share a common membrane-anchored scaffolding protein, caveolin. Caveolin binding negatively regulates the auto-activation of Src tyrosine kinases. J. Biol. Chem. 271:1996;29182-29190.
3. Oka N., Yamamoto M., Schwencke C., Kawabe J., Ebina T., Ohno S., et al. Caveolin interaction with protein kinase C. Isoenzyme-dependent regulation of kinase activity by the caveolin scaffolding domain peptide. J. Biol. Chem. 272:1997;33416-33421.
4. Couet J., Sargiacomo M., Lisanti M.P. Interaction of a receptor tyrosine kinase, EGF-R, with caveolins. Caveolin binding negatively regulates tyrosine and serine/threonine kinase activities. J. Biol. Chem. 272:1997;30429-30438.
5. Razani B., Zhang X.L., Bitzer M., von Gersdorff G., Bottinger E.P., Lisanti M.P. Caveolin-1 regulates transforming growth factor (TGF)-beta/SMAD signaling through an interaction with the TGF-beta type I receptor. J. Biol. Chem. 276:2001;6727-6738.
6. Galbiati F., Volonte D., Brown A.M., Weinstein D.E., Ben-Ze'ev A., Pestell R.G., et al. Caveolin-1 expression inhibits Wnt/beta-catenin/Lef-1 signaling by recruiting beta-catenin to caveolae membrane domains. J. Biol. Chem. 275:2000;23368-23377.
7. Felley-Bosco E., Bender F.C., Courjault-Gautier F., Bron C., Quest A.F. Caveolin-1 down-regulates inducible nitric oxide synthase via the proteasome pathway in human colon carcinoma cells. Proc. Natl. Acad. Sci. USA. 97:2000;14334-14339.
8. Glenney J.R. Jr, Soppet D. Sequence and expression of caveolin, a protein component of caveolae plasma membrane domains phosphorylated on tyrosine in Rous sarcoma virus-transformed fibroblasts. Proc. Natl. Acad. Sci. USA. 89:1992;10517-10521.
9. Scherer P.E., Okamoto T., Chun M., Nishimoto I., Lodish H.F., Lisanti M.P. Identification, sequence, and expression of caveolin-2 defines a caveolin gene family. Proc. Natl. Acad. Sci. USA. 93:1996;131-135.
10. Tang Z., Scherer P.E., Okamoto T., Song K., Chu C., Kohtz D.S., et al. Molecular cloning of caveolin-3, a novel member of the caveolin gene family expressed predominantly in muscle. J. Biol. Chem. 271:1996;2255-2261.
11. Lee S.W., Reimer C.L., Oh P., Campbell D.B., Schnitzer J.E. Tumor cell growth inhibition by caveolin re-expression in human breast cancer cells. Oncogene. 16:1998;1391-1397.
12. Racine C., Belanger M., Hirabayashi H., Boucher M., Chakir J., Couet J. Reduction of caveolin 1 gene expression in lung carcinoma cell lines. Biochem. Biophys. Res. Commun. 255:1999;580-586.
13. Bender F.C., Reymond M.A., Bron C., Quest A.F. Caveolin-1 levels are down-regulated in human colon tumors, and ectopic expression of caveolin-1 in colon carcinoma cell lines reduces cell tumorigenicity. Cancer Res. 60:2000;5870-5878.
14. Razani B., Altschuler Y., Zhu L., Pestell R.G., Mostov K.E., Lisanti M.P. Caveolin-1 expression is down-regulated in cells transformed by the human papilloma virus in a p53-dependent manner. Replacement of caveolin-1 expression suppresses HPV-mediated cell transformation. Biochemistry. 39:2000;13916-13924.
15. Wiechen K., Sers C., Agoulnik A., Arlt K., Dietel M., Schlag P.M., et al. Down-regulation of caveolin-1, a candidate tumor suppressor gene, in sarcomas. Am. J. Pathol. 158:2001;833-839.
16. Koleske A.J., Baltimore D., Lisanti M.P. Reduction of caveolin and caveolae in oncogenically transformed cells. Proc. Natl. Acad. Sci. USA. 92:1995;1381-1385.
17. Hurlstone A.F., Reid G., Reeves J.R., Fraser J., Strathdee G., Rahilly M., et al. Analysis of the CAVEOLIN-1 gene at human chromosome 7q31.1 in primary tumours and tumour-derived cell lines. Oncogene. 18:1999;1881-1890.
18. Engelman J.A., Lee R.J., Karnezis A., Bearss D.J., Webster M., Siegel P., et al. Reciprocal regulation of neu tyrosine kinase activity and caveolin-1 protein expression in vitro and in vivo. Implications for human breast cancer. J. Biol. Chem. 273:1998;20448-20455.
19. Yang G., Truong L.D., Timme T.L., Ren C., Wheeler T.M., Park S.H., et al. Elevated expression of caveolin is associated with prostate and breast cancer. Clin. Cancer Res. 4:1998;1873-1880.
20. Yang G., Truong L.D., Wheeler T.M., Thompson T.C. Caveolin-1 expression in clinically confined human prostate cancer: a novel prognostic marker. Cancer Res. 59:1999;5719-5723.
21. Davidson B., Nesland J.M., Goldberg I., Kopolovic J., Gotlieb W.H., Bryne M., et al. Caveolin-1 expression in advanced-stage ovarian carcinoma - a clinicopathologic study. Gynecol. Oncol. 81:2001;166-171.
22. Kato K., Hida Y., Miyamoto M., Hashida H., Shinohara T., Itoh T., et al. Overexpression of caveolin-1 in esophageal squamous cell carcinoma correlates with lymph node metastasis and pathologic stage. Cancer. 94:2002;929-933.
23. Ito Y., Yoshida H., Nakano K., Kobayashi K., Yokozawa T., Hirai K., et al. Caveolin-1 overexpression is an early event in the progression of papillary carcinoma of the thyroid. Br. J. Cancer. 86:2002;912-916.
24. Glenney J.R. Jr, Zokas L. Novel tyrosine kinase substrates from Rous sarcoma virus-transformed cells are present in the membrane skeleton. J. Cell Biol. 108:1989;2401-2408.
25. Engelman J.A., Chu C., Lin A., Jo H., Ikezu T., Okamoto T., et al. Caveolin-mediated regulation of signaling along the p42/44 MAP kinase cascade in vivo. A role for the caveolin-scaffolding domain. FEBS Lett. 428:1998;205-211.
26. Galbiati F., Volonte D., Engelman J.A., Watanabe G., Burk R., Pestell R.G., et al. Targeted downregulation of caveolin-1 is sufficient to drive cell transformation and hyperactivate the p42/44 MAP kinase cascade. EMBO J. 17:1998;6633-6648.
27. Engelman J.A., Zhang X.L., Razani B., Pestell R.G., Lisanti M.P. p42/44 MAP kinase-dependent and -independent signaling pathways regulate caveolin-1 gene expression. Activation of Ras-MAP kinase and protein kinase a signaling cascades transcriptionally down-regulates caveolin-1 promoter activity. J. Biol. Chem. 274:1999;32333.
28. Li S., Couet J., Lisanti M.P. Src tyrosine kinases, Galpha subunits, and H-Ras share a common membrane-anchored scaffolding protein, caveolin. Caveolin binding negatively regulates the auto-activation of Src tyrosine kinases. J. Biol. Chem. 271:1996;29182-29190.
29. Couet J., Sargiacomo M., Lisanti M.P. Interaction of a receptor tyrosine kinase, EGF-R, with caveolins. Caveolin binding negatively regulates tyrosine and serine/threonine kinase activities. J. Biol. Chem. 272:1997;30429-30438.
30. Liu J., Razani B., Tang S., Terman B.I., Ware J.A., Lisanti M.P. Angiogenesis activators and inhibitors differentially regulate caveolin-1 expression and caveolae formation in vascular endothelial cells. Angiogenesis inhibitors block vascular endothelial growth factor-induced down-regulation of caveolin-1. J. Biol. Chem. 274:1999;15781-15785.
31. Li S., Okamoto T., Chun M., Sargiacomo M., Casanova J.E., Hansen S.H., et al. Evidence for a regulated interaction between heterotrimeric G proteins and caveolin. J. Biol. Chem. 270:1995;15693-15701.
32. Razani B., Rubin C.S., Lisanti M.P. Regulation of cAMP-mediated signal transduction via interaction of caveolins with the catalytic subunit of protein kinase A. J. Biol. Chem. 274:1999;26353-26360.
33. Wiechen K., Diatchenko L., Agoulnik A., Scharff K.M., Schober H., Arlt K., et al. Caveolin-1 is down-regulated in human ovarian carcinoma and acts as a candidate tumor suppressor gene. Am. J. Pathol. 159:2001;1635-1643.
34. Hayashi K., Matsuda S., Machida K., Yamamoto T., Fukuda Y., Nimura Y., et al. Invasion activating caveolin-1 mutation in human scirrhous breast cancers. Cancer Res. 61:2001;2361-2364.
35. Cui J, Rohr LR, Swanson G, Speights VO, Maxwell T, Brothman AR. Hypermethylation of the caveolin-1 gene promoter in prostate cancer, Prostate 46:249-56.
36. Rajjayabun P.H., Garg S., Durkan G.C., Charlton R., Robinson M.C., Mellon J.K. Caveolin-1 expression is associated with high-grade bladder cancer. Urology. 58:2001;811-814.
37. Yoon S.S., Ahn K.S., Lee H.I. The roles of caveolin-1 gene in human renal cell carcinoma (HRCC). Proc. Am. Assoc. Cancer Res. 41:2000;273.
38. Lee H., Volonte D., Galbiati F., Iyengar P., Lublin D.M., Bregman D.B., et al. Constitutive and growth factor-regulated phosphorylation of caveolin-1 occurs at the same site (Tyr-14) in vivo: identification of a c-Src/Cav-1/Grb7 signaling cassette. Mol. Endocrinol. 14:2000;1750-1775.
39. Racine C., Belanger M., Hirabayashi H., Boucher M., Chakir J., Couet J. Reduction of caveolin 1 gene expression in lung carcinoma cell lines. Biochem. Biophys. Res. Commun. 255:1999;580-586.
40. Li L., Yang G., Ebara S., Satoh T., Nasu Y., Timme T.L., et al. Caveolin-1 mediates testosterone-stimulated survival/clonal growth and promotes metastatic activities in prostate cancer cells. Cancer Res. 61:2001;4386-4392.